Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status

Cancer Treatment and Research Communications - United Kingdom
doi 10.1016/j.ctarc.2017.09.001
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Phase 1 Trial of Olaparib and Oral Cyclophosphamide in BRCA Breast Cancer, Recurrent BRCA Ovarian Cancer, Non-Brca Triple-Negative Breast Cancer, and Non-Brca Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2019English

UK BRCA Mutation Testing in Patients With Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2015English

ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer

European Journal of Cancer
Cancer ResearchOncology
2017English

Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

An Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Bevacizumab in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Previously Treated With Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer: Rationale, Design, and Methods of the Japanese Gynecologic Oncology Group Study JGOG3023

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Phase II Trial of Lapatinib and Topotecan (LapTop) in Patients With Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma

Gynecologic Oncology
GynecologyOncologyObstetrics
2011English

Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

BRCA Mutation Breast Cancer Patients Show Equivalent Ovarian Reserve and Response to IVF Stimulation Compared to BRCA Negative Patients and Other Malignancies Undergoing Fertility Preservation

Fertility and Sterility
GynecologyReproductive MedicineObstetrics
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy